Effect of Different Color Lights on the Internal Clock and Alertness in Humans
NCT ID: NCT05423002
Last Updated: 2022-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
68 participants
INTERVENTIONAL
2022-06-20
2023-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Photomotor Reflex to Evaluate the Role of the Non-visual Effects of Light in Neurological, Psychiatric and Ophthalmological Pathologies
NCT03811964
Study of the Effects of Light Flashes on the Visual System
NCT02629471
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 7 of 7)
NCT02919137
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 4 of 7)
NCT02919228
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)
NCT02919189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Dim light condition as a baseline
Dim light
This light condition is the baseline (≤10 lux).
Modulation
Flickering light will be added sinusoidally onto the background light.
Flickering light stimuli
The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
Background
Constant light with maximum half irradiance (50%) of all primaries.
Constant light stimuli
The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flickering light stimuli
The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
Constant light stimuli
The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
Dim light
This light condition is the baseline (≤10 lux).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: male or female normal color vision, male dichromat (i.e. tested by CCT, HRR, Farnsworth Munsell 100 Hue Test)
* BMI: 18.5 - 29.9 self-reported weight and height (i.e. normal and overweight according to WHO)
* Signed consent form of participants
* Chronotype: Morningness-Eveningness Questionnaire (31 - 69)
* Sleep Quality: Pittsburgh Sleep Quality Index, PSQI (≤5)
Exclusion Criteria
* High hyperopia (\< +6 diopters)
* Transmeridian travel (\>2 time zones) \<1 month prior to the first session of the study
* Shift work \<3 months prior to the beginning of the study
* Ophthalmological or optometric conditions (cataract, glaucoma, retinal detachment, macular conditions, chronic inflammations, eye injuries, or operations)
* General health concerns or disorders, including heart and cardiovascular, neurological, nephrological, endocrinological, and psychiatric conditions
* Medication impacting on visual, neuroendocrine, sleep, and circadian physiology
* For females only: pregnancy, use of hormonal contraceptives, lactation or breastfeeding
* Drug (urinary drug screening) and alcohol use
* Non-compliance with sleep-wake times: \>1 deviation from ±30 minute window sleep and wake-up time
* Extreme chronotype (Munich Chronotype Questionnaire \<2 or \>7)
* Current participation in other clinical trials
* Inability to understand and/or follow study materials or procedures
* Insufficient knowledge of project language
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Horizon 2020 - European Commission
OTHER
University of Basel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatemeh Fazlali
Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Cajochen, Prof
Role: PRINCIPAL_INVESTIGATOR
Centre for Chronobiology, UPK, University of Basel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Chronobiology
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID 2022-00401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.